List of works - Marcel H.A. Muskiet

ACE-I vs. ARB for blood pressure control in diabetic kidney disease

scientific article published on 01 December 2014

Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes

scientific article published on 9 June 2016

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

scientific article published on April 2016

Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes

scientific article published on 25 November 2015

Assessment of real-time and quantitative changes in renal hemodynamics in healthy overweight males: Contrast-enhanced ultrasonography vs para-aminohippuric acid clearance

scientific article published on 26 August 2019

Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.

scientific article published on 23 July 2016

Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes

scientific article

Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine

scientific article published on 23 October 2019

Combining incretin-based drugs and RAAS inhibitors: more cons than pros?

scientific article published on 10 August 2014

Comment on Lovshin et al. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes. Diabetes Care 2017;40:1073-1081.

scientific article

Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.

scientific article

Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine

scientific article published on 01 February 2020

Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial

scientific article published on 4 February 2014

Ectopic Fat Storage in the Pancreas, Liver, and Abdominal Fat Depots: Impact on β-Cell Function in Individuals with Impaired Glucose Metabolism ⬇️

scientific article published on November 17, 2010

Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and its kidney clearance: post-hoc analyses of four clinical trials

scientific article published on 17 January 2018

Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial

scientific article published on 08 September 2020

Effects of DPP-4 inhibitor linagliptin versus sulfonylurea glimepiride on systemic haemodynamics in overweight patient with type 2 diabetes: a secondary analysis of an 8-week randomized controlled double-blind trial

scientific article published on 01 June 2020

Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes

scientific article published on 06 June 2020

Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050

scientific article published on 23 January 2019

Erratum. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care 2018;41:1543-1556

scientific article published on 20 August 2019

Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males

scientific article

GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men.

scientific article published on 23 April 2015

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes

scientific article published on 4 September 2017

GLP-1 based therapies: clinical implications for gastroenterologists.

scientific article

GLP-1 receptor agonists do not affect sodium intake: Exploratory analyses from two randomized clinical trials

scientific article published on 14 June 2019

GLP-1 receptor agonists, CKD, and eGFR trajectory

scientific article published on 01 October 2018

GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial

scientific article

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment

scientific article published on 31 January 2017

Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.

scientific article

High Prevalence of Intraductal Papillary Mucinous Neoplasms in Type 2 Diabetes Mellitus Patients

scientific article published on 01 January 2020

Incretin-based drugs and renoprotection—is hyperfiltration key?

scientific article published on 01 March 2015

Insulin Sensitivity and Renal Hemodynamic Function in Metformin-Treated Adults With Type 2 Diabetes and Preserved Renal Function

scientific article published on 29 October 2019

Letter by Muskiet et al Regarding Article, "Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial"

scientific article published on 01 August 2015

Liraglutide and Renal Outcomes in Type 2 Diabetes

scientific article published in November 2017

Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients

scientific article published on 18 June 2018

Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial

scientific article published on 03 October 2018

Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial.

scientific article

Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial

scientific article published on 14 December 2020

New pharmacological strategies for protecting kidney function in type 2 diabetes

scientific article published on 19 December 2018

Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial.

scientific article

Pancreatic Steatosis Is Not Associated With Exocrine Pancreatic Function in Overweight Type 2 Diabetes Patients.

scientific article

Pleiotropic effects of type 2 diabetes management strategies on renal risk factors.

scientific article

Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial

scientific article published on 27 April 2017

Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

scientific article published on September 2016

Renal outcomes in CVOTs: keep calm and carry on

scientific article published on 21 June 2018

Renal sinus fat and renal hemodynamics: a cross-sectional analysis

scientific article published on 31 August 2019

Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus

article

Renoprotection in LEADER and EMPA-REG OUTCOME

scientific article published on 01 October 2016

Role of Insulin-Stimulated Adipose Tissue Perfusion in the Development of Whole-Body Insulin Resistance

scientific article published on 26 January 2017

SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.

scientific article

SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management

scientific article published on 01 August 2018

SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise

scientific article published on 18 November 2020

SGLT2 inhibition: a new era in renoprotective medicine?

scientific article published on 27 June 2017

SGLT2 inhibitors: expanding their Empire beyond diabetes

scientific article published on 22 December 2020

Should dietary SFA be exchanged for linoleic acid? ⬇️

scientific article published on 01 October 2012

The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients.

scientific article published on 27 December 2016

The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?

scientific article published on 24 December 2013

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

scientific article published on 10 October 2019

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.

scientific article published on 15 September 2016

Uncomplicated human type 2 diabetes is associated with meal-induced blood pressure lowering and cardiac output increase

scientific article published on 7 October 2014

Understanding EMPA-REG OUTCOME

scientific article published on 01 December 2015

List of works by Marcel H.A. Muskiet

ACE-I vs. ARB for blood pressure control in diabetic kidney disease

Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes

Assessment of real-time and quantitative changes in renal hemodynamics in healthy overweight males: Contrast-enhanced ultrasonography vs para-aminohippuric acid clearance

Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.

Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes

Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine

Combining incretin-based drugs and RAAS inhibitors: more cons than pros?

Comment on Lovshin et al. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes. Diabetes Care 2017;40:1073-1081.

Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.

Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine

Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial

Ectopic Fat Storage in the Pancreas, Liver, and Abdominal Fat Depots: Impact on β-Cell Function in Individuals with Impaired Glucose Metabolism ⬇️

Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and its kidney clearance: post-hoc analyses of four clinical trials

Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial

Effects of DPP-4 inhibitor linagliptin versus sulfonylurea glimepiride on systemic haemodynamics in overweight patient with type 2 diabetes: a secondary analysis of an 8-week randomized controlled double-blind trial

Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes

Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050

Erratum. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care 2018;41:1543-1556

Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males

GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men.

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes

GLP-1 based therapies: clinical implications for gastroenterologists.

GLP-1 receptor agonists do not affect sodium intake: Exploratory analyses from two randomized clinical trials

GLP-1 receptor agonists, CKD, and eGFR trajectory

GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment

Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.

High Prevalence of Intraductal Papillary Mucinous Neoplasms in Type 2 Diabetes Mellitus Patients

Incretin-based drugs and renoprotection—is hyperfiltration key?

Insulin Sensitivity and Renal Hemodynamic Function in Metformin-Treated Adults With Type 2 Diabetes and Preserved Renal Function

Letter by Muskiet et al Regarding Article, "Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial"

Liraglutide and Renal Outcomes in Type 2 Diabetes

Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients

Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial

Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial.

Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial

New pharmacological strategies for protecting kidney function in type 2 diabetes

Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial.

Pancreatic Steatosis Is Not Associated With Exocrine Pancreatic Function in Overweight Type 2 Diabetes Patients.

Pleiotropic effects of type 2 diabetes management strategies on renal risk factors.

Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial

Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Renal outcomes in CVOTs: keep calm and carry on

Renal sinus fat and renal hemodynamics: a cross-sectional analysis

Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus

Renoprotection in LEADER and EMPA-REG OUTCOME

Role of Insulin-Stimulated Adipose Tissue Perfusion in the Development of Whole-Body Insulin Resistance

SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.

SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management

SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise

SGLT2 inhibition: a new era in renoprotective medicine?

SGLT2 inhibitors: expanding their Empire beyond diabetes

Should dietary SFA be exchanged for linoleic acid? ⬇️

The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients.

The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.

Uncomplicated human type 2 diabetes is associated with meal-induced blood pressure lowering and cardiac output increase

Understanding EMPA-REG OUTCOME